Aurora Cannabis Stock (TSX: ACB) (NYSE: ACB) - Investor Dashboard

Aurora Cannabis
Market Focus: Global
Classification: Vertically Integrated
Country: Canada
Employees: ~3000 as of 09/2019
Established: 2013
Interim CEO: Michael Singer

Aurora Cannabis – Management Team

Michael Singer – Executive Chairman & Interim CEO

Michael Singer, previously Chairman of the Board, is the company’s Executive Chairman of the Board of Directors and Interim CEO. In this role, His previous experience includes serving as CFO of Clementia Pharmaceuticals and CFO of Bedrocan Cannabis Corp.

Steve Dobler, P. Eng – President

steve-dobler-peng-auroraSteve Dobler began his distinguished career in 1990 upon obtaining his Professional Engineering designation from the University of Alberta. Steve has held numerous executive positions in successful private and public Canadian companies over the past 25 years where he was responsible for the implementation of project management, strategies, and overseeing all facets of various operations. Currently serving as President for Alberta’s largest safety codes permitting company, his focus is on customers, innovation, and improved operational efficiencies which directly led to significant company growth. In 2011, the company was included in the top 50 of Canada’s fastest growing companies. Harvesting the initial idea of Aurora, Steve sought out the challenge shortly after identifying its potential. Personally investing $2 million of start up capital, Steve is largely responsible for the $8.6 million the company has raised to date.

Glen Ibbott – Chief Financial Officer

glenn-ibbott-aurora-cannabisGlen Ibbott is a seasoned senior healthcare executive with over 20 years’ experience providing financial leadership to various public entities, including management of Canadian and international capital market strategies, M&A, tax and finance, predominantly within the life sciences sector. An innovative, decisive, and insightful professional, he has excelled in delivering revenue and profitability growth, both domestically and internationally, strategy execution and shareholder value creation, including key contributions to numerous corporate transactions. Most recently, Mr. Ibbott was CFO at QLT Inc, a NASDAQ and TSX listed Biopharmaceutical Company and played a key role in QLT’s $500 million merger with Aegerion Pharmaceuticals to form Novelion Therapeutics. Prior to his time at QLT, Mr. Ibbott held various senior finance positions, including with globally operating companies such as Nordion, International Forest Products, Angiotech Pharmaceuticals, Aspreva Pharmaceuticals, and Inex Pharmaceuticals. Earlier in his career, he worked within the technology practice of KPMG. Mr. Ibbott completed MBAs at Cornell University and at Queen’s University, is a Canadian Chartered Professional Accountant (CPA, CA), as well as a US CPA, and holds a Bachelor’s of Business Administration from Simon Fraser University.

Allan Cleiren – Chief Operations Officer

Mr. Cleiren has nearly three decades of leadership experience in finance and operations management with both privately and publicly held companies in the life sciences, insurance, rail, construction, oil and gas service, and other sectors.. Most recently, Mr. Cleiren was COO with Jardine Lloyd Thompson Canada Inc. (JLT), one of the world’s leading providers of insurance, reinsurance and employee benefits related advice, brokerage and associated services. Prior to joining JLT, he served as Executive Vice President and formerly CFO for Universal Rail Systems Inc, and as Senior Vice President of Operations and CFO for Afexa Life Sciences. He is a member of the Board of Directors of Universal Rail Services Inc., Metalogic Inspection Services Inc., and is Chair of the Board for the Alberta Automobile Insurance Rate Board. Mr. Cleiren is a Chartered Professional Accountant (CPA, CA), holds a Bachelor of Commerce from the University of Alberta, and has a Diploma in Management Sciences from the Grant MacEwan College in Alberta. Mr. Cleiren also holds a ICD.D designation through the Institute of Corporate Directors.

Debra Wilson, PhD – Chief Human Resources Officer

Dr. Wilson joined Aurora Cannabis in 2017 as Vice President and Senior Vice President of Human Resources. In August 2018, she was promoted to Chief Human Resources Officer. Dr. Wilson completed her MBA at Royal Roads University and her PhD in industrial and organizational psychology at Capella University. Prior to joining Aurora, she held HR leadership positions at companies including Universal Rail Systems and Alberta Pensions Services Corporation.

Darryl Vleeming – Chief Information Officer

Aurora appointed Mr. Vleeming, previously Vice President of Information Systems and CIO of Capital Power Corporation, CIO in 2017. He was more than two decades of experience in senior IT leadership positions. Mr. Vleeming earned his Executive MBA from the University of Athabasca and his Computer Systems Technology Honors Diploma from the Northern Alberta Institute of Technology.

Jillian Swainson – Chief Legal Officer

Ms. Swainson is a former partner at Brownlee LLP. She has experience in corporate, commercial, intellectual property, and securities law. During her career, she has provided advisory services in highly regulated industries.

Darren Karasiuk – Chief Commerical Officer

Mr. Karasiuk is a former Vice President of Insights and Advisory at Deloitte. He successfully launched Aurora and its brands into the Canadian consumer market.

Jonathan Page, PhD – Chief Science Officer

Dr. Page is the co-founder of Anandia Labs. He co-led the team of scientists first responsible for sequencing the cannabis genome.

Dr. Shane Morris – Chief Product Officer

Dr. Morris joined Aurora in 2018 as the Senior Vice President of Product Development and Regulatory Affairs. In his new role as Chief Product Officer, Dr. Morris will be responisble for product development in the Canadian and international markets. He earned a PhD in plant science and policy from the National University of Ireland, Galway and a BSc in biology and mathematics from National University of Ireland, Maynooth.

André Jérôme – Chief Integration Officer

Mr. Jérôme joined Aurora in 2018 through the acquistion of H2 Biopharma. He has focused on the integration of the company’s acquistions. His role has now expanded to include global security, health, safety, and environment. Mr. Jérôme has led a number of successful integrations of Aurora’s assets, including CanniMed Therapeutics, MedReleaf, Whistler Cannabis, and Anandia Laboratories.

Significant Insider Ownership

Terry Booth
10.06mm shares

Steve Dobler, President
19.35mm shares

Visit Aurora Cannabis

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Aurora Cannabis is a client of NCV Media, LLC. Read our full disclaimer.